Muscle
15Protein synthesis, exercise recovery and lean-mass preservation.
GH & body compositionBlend
CJC-1295 (no DAC) / Ipamorelin Protocol
Two-component GH-axis combination
Community reportsGrowth hormone · body composition2
No FDA-approved product identified for this exact research entry in the targeted review.
What does it do?
A community combination of modified GRF(1–29) without DAC and ipamorelin. Specific combined benefits and safety lack clinical validation.
Approved & studied uses
No established medical use is documented for this formulation.
Evidence limits
View research →Combined benefit, optimal ratio and long-term safety remain unestablished.1
1 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Evidence limitation
FDA highlights inadequate toxicity evidence for no-DAC CJC forms.1
No FDA-approved product identified for this exact research entry in the targeted review.
Molecular information
Amino-acid sequence
This blend contains multiple compounds and has no single amino-acid sequence.
Multiple componentsComposition varies
LengthTwo components
Molecular weight · DaComponent specific
Formula, sequence notation & identity
Molecular formulaNo single molecular formula1
CJC-1295 no DAC / modified GRF(1–29) plus ipamorelin
Ratio and CJC form must be identified; DAC CJC is a different molecule.
Pharmacokinetics
How long does it stay in the body?
Reported half-lifeHuman half-life not verified2
No numerical human elimination estimate was verified for the exact material in this review.
What to expect
Study outcomes
Component studies do not validate the combination
Combined benefit, optimal ratio and long-term safety remain unestablished.1
Reported timelines
Reference & communityWeeks 1–2 / 3–4 / 6–8 / 8–12
Reference/community sequence: sleep/dreams; recovery/energy; composition/skin; maximum effects. Post-treatment persistence claims unvalidated.15
These are reported timelines, not a prediction of your response.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
The source hides 5 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Age range
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 10 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 29 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 35 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
The source hides 11 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Would recommend
The source hides 17 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
The source hides 6 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “4053 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQ | 200 mcg each (0.2 mL if 1 mg/mL) | Once daily before bed | General health optimizationReference report | 8-12 weeks on, 4 weeks off recommended to maintain receptor sensitivity | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| SubQ | 100-150 mcg each (0.1-0.15 mL if 1 mg/mL) | Twice daily (AM + before bed) | Enhanced GH pulsatilityReference report | 8-12 weeks on, 4 weeks off recommended to maintain receptor sensitivity | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| SubQ | 250 mcg each (0.25 mL if 1 mg/mL) | Once daily before bed | Performance enhancementReference report | 8-12 weeks on, 4 weeks off recommended to maintain receptor sensitivity | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| SubQ | 300 mcg each (0.3 mL if 1 mg/mL) | Once daily before bed | Recovery optimizationReference report | 8-12 weeks on, 4 weeks off recommended to maintain receptor sensitivity | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| SubQ | 150 mcg each (0.15 mL if 1 mg/mL) | 5 days per week | Conservative approachReference report | 8-12 weeks on, 4 weeks off recommended to maintain receptor sensitivity | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 8-12 weeks on, 4 weeks off recommended to maintain receptor sensitivity
- Break
- 4 week minimum breaks help preserve natural GH production and receptor responsiveness
Reported timing
Once daily: 30-60 min before bed. Twice daily: morning (fasted) + before bed. Maintain 2-3 hour fast before each dose
Side effects & safety
Evidence limitation
FDA highlights inadequate toxicity evidence for no-DAC CJC forms.
1Evidence limitation
Small DAC-component studies cannot characterize safety of this combination.
1Symptoms
Joint swelling/pain, glucose changes, fatigue/mood changes, numbness/tingling, injection infection or unexpected tissue growth need assessment.
Limitations
GH/IGF-1 effects raise glucose and growth-related concerns; certificates do not establish clinical safety.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
7 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
MK-677
Caution reportedOverlapping GH/IGF-1 effects.15
Reference report · Pep-Pedia label: Monitor CombinationInsulin
Caution reportedInsulin sensitivity/glucose effects.15
Reference report · Pep-Pedia label: Monitor CombinationSynthetic HGH
Avoidance reportedRedundant GH exposure.15
Reference report · Pep-Pedia label: Avoid CombinationCorticosteroids
Caution reportedCan alter GH responses; not a dose-adjustment instruction.15
Reference report · Pep-Pedia label: Use CautionBPC-157
Unverified pairingReported GH-signaling/tissue-repair complement; untested.15
Reference report · Pep-Pedia label: CompatibleThyroid medications
Unverified pairingReference 4-hour separation lacks established support.15
Reference report · Pep-Pedia label: Requires TimingOther growth-hormone pathway agents
Not establishedA component review does not establish safety or magnitude of combined hormonal effects.1
Research contextNo matching interactions. Try another name or filter.
Reconstitution
No product-specific preparation or stability instruction was verified. A dilution calculation does not establish suitability for injection.2
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia describes preparation for this route; product-specific stability has not been independently verified.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- Source temperature: 2-8°C.
The source describes gentle mixing and avoiding vigorous shaking.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceStandard format labelingReported variationFormat selection guidanceReported appearance1:1 ratio maintenanceReported appearanceClear reconstitutionReported appearanceCertificate of AnalysisReported appearanceProper cold chainReported concernPoor storage indicatorsReported variationResearch limitationsReported variationDAC vs No-DAC clarity
15Available forms
No verified packaging examples included.
Amounts are total blend mass. Formulas and ratios vary. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Full storage notes from Pep-Pedia
15Refrigerate reconstituted peptides at 2-8°C. Use within 30 days of reconstitution for optimal potency
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Research findings
No blend trialsCompound identity & other names
This entry covers CJC-1295 without DAC plus ipamorelin. Component studies and long-acting CJC-1295 with DAC studies do not establish the combined no-DAC schedule.
No FDA-approved product identified for this exact research entry in the targeted review.
How it may work
GHRH and ghrelin receptors can stimulate GH through different pathways; synergy does not establish outcomes.15
Component studies do not validate the combination
Popular no-DAC CJC/ipamorelin schedules differ from the long-acting DAC formulation in published CJC trials. A controlled human trial of the exact combination was not verified.
1Research areas and evidence gaps
- Combined benefit, optimal ratio and long-term safety remain unestablished.
- A product-specific research-vial quantity was not independently verified in this review.
Community reports Unvalidated
Pep-Pedia discusses gh-axis and recovery interest.2
Editorial summary, not a measured community survey, clinical protocol or recommendation.
Search coverage and review status
No controlled human trial of the exact combination was verified. FDA distinguishes DAC-component evidence from no-DAC preparations.
- Checked
- 2026-10-12
- Search
- "CJC-1295" "ipamorelin" trial 2025 2026
- Catalog
- Pep-Pedia ↗ · 12 listed references retained
- Targeted search and selected primary-source checks, not an exhaustive systematic review.
- Preserved bibliography entries marked unreviewed have not had their findings independently verified.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1FDA review of CJC-1295-related bulk drug substancesPrimary source checked
AI-PREPARED SUMMARY
FDA found that published human CJC studies appeared to use the DAC form. They do not establish effectiveness of no-DAC CJC or a CJC/ipamorelin combination.
Component studies do not validate the combination
Popular no-DAC CJC/ipamorelin schedules differ from the long-acting DAC formulation in published CJC trials. A controlled human trial of the exact combination was not verified.
Additional research · Checked 2026-10-12
2Pep-Pedia: CJC-1295 (no DAC) / Ipamorelin ProtocolCommunity source checked
AI-PREPARED SUMMARY
Secondary editorial profile and reported practices; not clinical validation.
3CJC-1295 with DAC Clinical Efficacy - Teichman et al. (2006)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: This study concerned albumin-binding CJC-1295 with DAC; its reported 5.8–8.1-day half-life cannot be assigned to a no-DAC combination.
Reported population / model
Human
Reported study details
30-60 mcg/kg · 28-49 days · CJC-1295 WITH DAC version
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
4GH Pulsatility Preservation - Ionescu & Frohman (2006)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports retained GH pulses despite a 7.5-fold rise in basal GH; the formulation must be checked before applying this to a blend.
Reported population / model
Human
Reported study details
Continuous monitoring · 14 days · Maintained natural rhythm
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5GHS Receptor Desensitization - Camiña et al. (2004)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Cultured receptors desensitized quickly and recovered over about six hours. Cell-receptor timing does not validate a human dosing schedule.
Reported population / model
Cell culture
Reported study details
GHSR1a receptors · ~6 hour recovery time after stimulation
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6GHRH-GHS Receptor Interaction - Cunha & Mayo (2002)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Cells expressing both receptor systems showed a larger GHRH-driven cAMP response; this does not establish clinical combination efficacy.
Reported population / model
Cell culture
Reported study details
Transfected receptors · Enhanced cAMP production
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Ipamorelin Selectivity - Raun et al. (1998)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Ipamorelin reportedly stimulated GH without ACTH/cortisol changes at tested exposures; the finding does not establish the safety of a CJC blend.
Reported population / model
Multiple species
Reported study details
Various doses · Selective GH release without ACTH/cortisol effects
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adultsPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: This study concerned albumin-binding CJC-1295 with DAC; its reported 5.8–8.1-day half-life cannot be assigned to a no-DAC combination.
Reported population / model
Human
Reported study details
30-60 mcg/kg · 28-49 days · CJC-1295 WITH DAC version
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Ipamorelin, the first selective growth hormone secretagoguePep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Ipamorelin reportedly stimulated GH without ACTH/cortisol changes at tested exposures; the finding does not establish the safety of a CJC blend.
Reported population / model
Multiple species
Reported study details
Various doses · Selective GH release without ACTH/cortisol effects
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
10Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports retained GH pulses despite a 7.5-fold rise in basal GH; the formulation must be checked before applying this to a blend.
Reported population / model
Human
Reported study details
Continuous monitoring · 14 days · Maintained natural rhythm
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
11Ghrelin and growth hormone secretagogues potentiate GHRH-induced cAMP productionPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Cells expressing both receptor systems showed a larger GHRH-driven cAMP response; this does not establish clinical combination efficacy.
Reported population / model
Cell culture
Reported study details
Transfected receptors · Enhanced cAMP production
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
12Molecular recognition of an acyl-peptide hormone and activation of ghrelin receptorLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
13Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteersLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
14Desensitization and endocytosis mechanisms of ghrelin-activated growth hormone secretagogue receptor 1aPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Cultured receptors desensitized quickly and recovered over about six hours. Cell-receptor timing does not validate a human dosing schedule.
Reported population / model
Cell culture
Reported study details
GHSR1a receptors · ~6 hour recovery time after stimulation
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
15Pep-Pedia: CJC-1295 (no DAC) / Ipamorelin Protocol — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12
16Modified GRF 1-29 PharmacokineticsPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Pep-Pedia estimates 30 minutes to two hours for the no-DAC analogue. It supplies no original PK study link, so this is not a verified human measurement.
Reported population / model
Human
Reported study details
Various doses · Short-acting GHRH analog
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12